Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2
Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data
On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).
"We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs."
Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3.
Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course.
About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.
About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:Annie J. Cheng, CFAir@perspectivetherapeutics.com
Russo Partners, LLCNic JohnsonPerspectiveIR@russopr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
43 minutes ago
- Bloomberg
Trump's Twists and Turns Over Iran Leave Oil Traders Hanging
The oil market is wrestling with Donald Trump's next act in the conflict between Iran and Israel, with the US president's every utterance over the fighting seemingly capable of spiking or crashing prices. In a wild week, Brent futures have surged 11% from before Israel attacked its nemesis, but with sharp moves up and down from one day to the next.
Yahoo
43 minutes ago
- Yahoo
Is Net Worth More Important Than A High Salary? Some Say Yes, Others Argue A High Salary With Low Net Worth Is 'Much Easier To Fix'
When a Reddit user recently posted a rant claiming that net worth is more important than salary, it sparked a heated debate. The post criticized people who flaunt six-figure incomes but have little to show for it. The author questioned the value of a high paycheck if it all disappears to debt and lifestyle costs. 'Who cares what you make if you are still broke,' they wrote. The poster argued that plenty of six-figure earners live paycheck to paycheck and flex their income despite being buried in debt. 'I would rather make 50k a year and have 250k NW, than 150k a year and be in debt,' they wrote, adding, 'Having high NW displays financial discipline and competence.' Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Some people agreed, pointing out that income is only one part of the story. 'I worked with a guy who made over 100k,' one commenter wrote. 'Refused to save anything, not even 401(k). He bought anything and everything he wanted. He's still doing it.' Others pushed back, saying a high salary gives you more options and flexibility. 'Give me the high salary and low net worth. Much easier to fix,' one person said. Another argued, 'That 150k [salary] can erase debt and build a 250k NW a hell of a lot faster than the 50k / 250k one can increase.' A more detailed reply laid out how someone earning $150,000 could contribute aggressively to retirement, get employer matches, and outpace someone with a smaller income within a few years. 'You could waste ALL of your 126.5K minus taxes and end up with a quarter mill in 5 years,' the commenter explained. Trending: Maximize saving for your retirement and cut down on taxes: . Despite disagreements, one consistent theme emerged: discipline matters more than raw numbers. 'If you have an uncontrollable spending problem, it doesn't matter how much you make,' a user wrote. 'You can make 1 million a year and if you still spend 1.2 million you're an idiot.' Another summed it up this way: 'Net worth isn't always a sign of discipline but your post is well taken. If I made a million dollars per year for one year it doesn't make you rich.' Several pointed out that net worth often includes illiquid assets like homes, which can inflate the numbers without improving someone's day-to-day finances. 'You can't access your 401(k) without paying a penalty... unless your net worth is mostly comprised of cash in a mattress, a low salary and high net worth won't increase your buying power,' one user the end, some people argued that the best position is to have both: a strong income and disciplined saving habits. Consistent contributions to your retirement—while increasing the percentage over time— and positive cash flow are even more important, as those will build your net worth over time. A high income can fuel savings and investment, while net worth provides security when income slows down. Building both and understanding how they support each other is what creates lasting financial stability. Read Next: Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Is Net Worth More Important Than A High Salary? Some Say Yes, Others Argue A High Salary With Low Net Worth Is 'Much Easier To Fix' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
ThinkCareBelieve: Week 22 of America's Rise to Greatness under President Trump's Leadership
Washington, DC, June 21, 2025 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Article: has published an article about Week 22 of America's rise to greatness. This week entailed outstanding leadership by a steady hand through choppy waters and ThinkCareBelieve's article shows how the President kept moving forward at a strong, surefooted pace. ThinkCareBelieve's article has important progress made at the G7 and the signing of major trade agreements as tensions between Iran and Israel took place. The message from Press Secretary Karoline Leavitt this week was "Trust in President Trump." Great nations are made because of great leaders and this week was proof of it. America has just had the highest wage increase in 60 years and the article has it. Real blue collar wages are up nearly 2%! America's low inflation and rising wages is a sure sign of success. Two new 88 foot high flag poles were installed this week, a magnificent addition to the White House grounds. The article has the latest on the status of student visas from Secretary of State Marco Rubio and President Trump's approval numbers keep going up! The article covers the Genius Act being passed by the Senate and the announcement that 70,000 people have signed up for President Trump's Gold Card Visa. The article has an abundance of reasons the One Big Beautiful Bill will benefit Americans. The OBBB will drive growth and supercharge the American economy. The article even has a tax-free tips and overtime calculator to see the average savings in your state: The article has statements by Dr. OZ the Administrator of the Center for Medicaid and Medicare Services on just how the One Big Beatiful Bill will help the most vulnerable of us who will suffer if the OBBB is not passed. The article also covers the great strides made by Secretary Kennedy convincing major food manufacturers to remove artificial food dyes and chemicals from their foods. The article also has an announcement by U.S. Attoney Jeanine Pirro of the U.S. Department of Justice crackdown on Crypto Currency Confidence Scams with confiscation and seizure of stolen money being returned back to the victims. Numerous investigations commenced this week and ThinkCareBelieve's article has the surge in attacks on ICE as they tried to do their jobs arresting criminal illegal aliens, catching child predators and dismantling trafficking networks. President Trump is the Man in the Arena and we are witessing history seeing how this man leads us through the muck and the mire to peace and prosperity in America's Golden Age. is an outlook. ThinkCareBelieve's mission for Peace advocacy facilitates positive outcomes and expanded possibilities. To achieve Peace, we will find the commonalities between diverse groups and bring the focus on common needs, working together toward shared goals. Activism is an important aspect of ThinkCareBelieve, because public participation and awareness to issues needing exposure to light leads to justice. Improved transparency in government can lead to changes in policy and procedure resulting in more fluid communication between the public and the government that serves them. America needs hope right now, and Americans need to be more involved in their government. ### CONTACT: CONTACT: Joanne COMPANY: ThinkCareBelieve EMAIL: joanne@ WEB: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
